Amylyx’s Relyvrio/Albrioza Launch Chugs Along As Firm Gives EU Another Go
Executive Summary
The company reported 3,800 ALS patients on drug, a figure that came in slightly below some analyst estimates but which suggested discontinuation rates consistent with the pivotal trial.